Log-in / Create Account  
Session Information
2007 BIO International Convention
Click here to go to the previous page
Predicting Safety and Efficacy of New Medicines—European and U.S. Initiatives
Track : Drug Discovery and Development
Program Code: DDD050
Date: Wednesday, May 9, 2007
Time: 11:00 AM to 12:30 PM  
Location: 259 AB
CHAIR :
Ian Ragan, European Scientific Affairs, Eli Lilly and EFPIA Research Directors' Group
SPEAKER (S):
Friedlieb Pfannkuch, Vice-Director, F. Hoffmann-La Roche Ltd.
 William Mattes, Director of Toxicology, The Critical Path Institute MD, United States
Simon Lovestone, Professor of Old Age Psychiatry, Institute of Psychiatry, King's College London
DR Janet Woodcock, MD, Deputy Commissioner and Chief Medical Officer, FDA, MD, United States
Description
Initiatives such as the Critical Path in the United States and the Innovative Medicines Initiative (IMI) address the needs for new approaches to produce safe drugs more efficiently and quickly. In this session you will learn more about the first research projects from these initiatives and the results achieved so far.



Objectives:
  • Get an overview of U.S. and European initiatives aiming at reducing attrition in the drug development process.

  • Learn more about the different research approaches taken, and the first results, in the first projects under the U.S. Critical Path Initiative and the European Innovative Medicines Initiative.

  • Learn more about the progress of the implementation of the Critical Path Initiative and of the Innovative Medicines Initiative.

    • Streaming Audio with
    PowerPoint Slides
    (Code: DDD050)
      
    This session is a part of:
    Drug Discovery and Development 2-DAY TRACK
    Complete Set of BIO Online / CD-ROM - All 23 Tracks.